Downregulation of RASSF6 is involved in neuroblastoma, melanoma, nasopharyngeal cancer and childhood acute lymphocytic leukemia, and its decreased expression level is also associated with poor survival of pancreatic ductal adenocarcinoma and gastric cancer [9–12, 14, 15]. The gene discussed is RASSF6; the disease is melanoma.